Company Filing History:
13 out of 20 
2 out of 2 
1 out of 1 Years Active: 2004-2017
Title: The Innovative Journey of Salman Al-Mahmood
Introduction: Salman Al-Mahmood is a prominent inventor based in Paris, France, known for his significant contributions to the field of medical innovation. With a remarkable portfolio of 16 patents, Al-Mahmood has dedicated his career to developing solutions that address various health-related challenges. His work primarily focuses on compositions that target specific pathways involved in angiogenic diseases and skin disorders.
Latest Patents: Among Al-Mahmood's latest patents are two groundbreaking inventions. The first patent is titled "Composition comprising inhibitors of IRS-1 and of VEGF." This invention consists of a composition or kit containing an inhibitor of IRS-1 and an inhibitor of the VEGF pathway, which is aimed at treating angiogenic diseases. The second patent is "Inhibitor of IRS-1 for treating skin disorders." This invention elaborates on the use of an inhibitor of IRS-1 expression in treating angiogenic and inflammatory skin diseases, and introduces a transdermal composition, preferably an ointment, designed for effective treatment.
Career Highlights: Throughout his career, Salman Al-Mahmood has collaborated with various companies, notably Gene Signal International SA and Gene Signal. His unique expertise in the field has allowed him to contribute to innovative research and development efforts, positioning him as a valuable asset in the biotechnology sector.
Collaborations: Al-Mahmood has worked alongside talented colleagues such as Sylvie Colin and Christophe Schneider. Their collaborative efforts have led to significant advancements in the understanding and treatment of complex medical conditions, demonstrating the power of teamwork in driving innovation.
Conclusion: Salman Al-Mahmood's commitment to innovation and success in obtaining multiple patents exemplifies his role as a leading inventor in medical technologies. His contributions in developing novel treatment options for angiogenic diseases and skin disorders reflect his dedication to improving healthcare outcomes. As he continues to push boundaries in his research, we can expect further advancements that will benefit society at large.